Thank you for being on the MIND Study journey with us! Enrollment for the MIND Study is complete, all participants have completed the study, and topline study results are ready to share.

With this, below is the announcement about the MIND Study results:

The MIND Study tested a wearable patch over a two-year period, and included people diagnosed with Mild Cognitive Impairment (also known as MCI) or mild memory loss. Unfortunately, overall study results show that the investigational treatment of nicotine administered through a wearable patch over a two-year period did not slow memory loss compared to the placebo treatment.

Although the overall study results are negative, researchers were able to uncover new information about how nicotine interacts with the brain. This information will be very important and help both ongoing and future clinical trials of other treatments for memory loss. Even clinical trials that fail to generate positive results still produce vitally important information that benefits the field of Alzheimer's disease research.

Please view a video message below from the MIND Study Lead Investigator

If you are interested in learning more about the MIND Study results, please see the slides below that were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego on December 4, 2025.

If you took part in the MIND Study as a participant and would like to learn more—or if you’d like to receive a copy of your individual study results—please be sure to contact your study site team directly where you were a participant in the study. More information is available about the study results through your study site.

The MIND Study team wants to extend our special gratitude for your important contribution to Alzheimer’s disease research. Your participation in the MIND Study will help us move science forward and will help bring us closer to new discoveries.